ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer

NCT04523857 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Abemaciclib
DRUG: Hydroxychloroquine

Sponsor

Abramson Cancer Center at Penn Medicine